Antimicrobial drug developer HOOKIPA Pharma (NASDAQ:HOOK) announced Thursday that Gilead Sciences (NASDAQ:GILD) has agreed to acquire some of its assets for a total consideration of up to $10M.

Under the terms of the agreement, Gilead will provide an upfront payment of $10 million. Additionally, Hookipa will be eligible to receive milestone payments based upon the achievement of ...

Gilead purchased 15 million shares and holds 19.4% stake in HOOKIPA. Equity investment is to advance the Gilead-partnered HIV program through Phase 1 trial expected to start in 1H of 2024.

Gilead holds 19.4% of HOOKIPA’s outstanding shares of common stock Equity investment is to advance the Gilead-partnered HIV therapeutic program through Phase 1; trial expected to commence in the ...

HB-400 (NCT05770895) is currently being evaluated in a Phase 1 trial and is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead Sciences ...

Gilead is solely responsible for further development and commercialization of the hepatitis B product candidate. HOOKIPA is eligible to receive milestone payments based on the achievement of ...

Gilead is solely responsible for further development and commercialization of HB-400, referenced as GS-2829 and GS-6779. HOOKIPA earned a $5 million non-dilutive payment under its collaboration ...